MCID: GST105
MIFTS: 42

Gastroesophageal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Adenocarcinoma:

Name: Gastroesophageal Adenocarcinoma 12 15
Gastric and Esophageal Adenocarcinoma 12
Gastro-Esophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080375

Summaries for Gastroesophageal Adenocarcinoma

Disease Ontology : 12 A gastroesophageal cancer that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Gastroesophageal Adenocarcinoma, also known as gastric and esophageal adenocarcinoma, is related to adenocarcinoma and mucositis. An important gene associated with Gastroesophageal Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Actin Nucleation by ARP-WASP Complex and Focal Adhesion. The drugs Levoleucovorin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Gastroesophageal Adenocarcinoma

Diseases related to Gastroesophageal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.7 PTEN MST1R MET ERBB2 EGFR
2 mucositis 30.2 XRCC1 TYMS MTHFR MET
3 diffuse gastric cancer 29.5 MTR GSTT1 GSTP1 GSTM1 ERCC2 ERCC1
4 esophageal cancer 29.3 XRCC1 TYMS PTEN MTHFR GSTP1 GSTM1
5 gastric cancer 28.5 XRCC1 UMPS TYMS PTEN MTHFR MET
6 bladder cancer 27.9 XRCC1 TYMS SRC PTEN GSTT1 GSTP1
7 lung cancer 26.9 XRCC1 XPA UGT1A1 TYMS SRC PTEN
8 neutropenia 10.4
9 gastroesophageal junction adenocarcinoma 10.4
10 hemifacial spasm 10.4 TYMS MTHFR
11 gastric adenocarcinoma 10.4
12 hearing loss, noise-induced 10.3 GSTT1 GSTM1
13 cerebro-oculo-facio-skeletal syndrome 10.3 ERCC2 ERCC1
14 sudden sensorineural hearing loss 10.3 MTR MTHFR
15 breast scirrhous carcinoma 10.3 ERBB2 EGFR
16 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 10.3 MTR MTHFR
17 gastric cardia carcinoma 10.3 XRCC1 MTHFR
18 isolated cleft lip 10.3 GSTT1 GSTM1
19 mixed phenotype acute leukemia 10.3 MTHFR GSTM1 ERCC2
20 multiple chemical sensitivity 10.2 MTHFR GSTP1 GSTM1
21 beta-thalassemia major 10.2 MTHFR GSTT1 GSTM1
22 xeroderma pigmentosum, complementation group f 10.2 XPA ERCC2 ERCC1
23 xeroderma pigmentosum group e 10.2 XPA ERCC2 ERCC1
24 breast metaplastic carcinoma 10.2 ERBB2 EGFR
25 xeroderma pigmentosum, complementation group b 10.2 XPA ERCC2 ERCC1
26 submandibular gland cancer 10.2 ERBB2 EGFR
27 exfoliation syndrome 10.2 MTHFR GSTP1 GSTM1
28 methotrexate toxicity 10.2 TYMS MTR MTHFR
29 asbestosis 10.2 GSTT1 GSTP1 GSTM1
30 uv-sensitive syndrome 10.2 XPA ERCC2 ERCC1
31 trichothiodystrophy 10.2 XPA ERCC2 ERCC1
32 female breast cancer 10.2 XRCC1 ERCC2 ERBB2
33 lung non-squamous non-small cell carcinoma 10.2 TYMS ERBB2 EGFR
34 sister chromatid exchange, frequency of 10.2 XRCC1 GSTT1 GSTM1
35 primary peritoneal carcinoma 10.2 ERCC1 ERBB2 EGFR
36 oral leukoplakia 10.2 XRCC1 GSTT1 GSTM1
37 breast malignant phyllodes tumor 10.2 ERBB2 EGFR
38 adult acute lymphocytic leukemia 10.2 TYMS MTR MTHFR
39 oligospermia 10.2 GSTT1 GSTP1 GSTM1
40 xeroderma pigmentosum, complementation group c 10.2 XRCC1 XPA ERCC1
41 senile cataract 10.2 XRCC1 GSTT1 GSTM1
42 progesterone-receptor negative breast cancer 10.2 ERBB2 EGFR
43 doxorubicin induced cardiomyopathy 10.1 MET EGFR
44 childhood leukemia 10.1 TYMS MTR MTHFR
45 biliary tract cancer 10.1 MET ERBB2 EGFR
46 oral cancer 10.1 GSTT1 GSTM1 EGFR
47 thyroid tumor 10.1 PTEN GSTT1 GSTM1
48 diarrhea 10.1
49 paronychia 10.1 ERBB2 EGFR
50 xeroderma pigmentosum, complementation group a 10.1 XRCC1 XPA ERCC2 ERCC1

Graphical network of the top 20 diseases related to Gastroesophageal Adenocarcinoma:



Diseases related to Gastroesophageal Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Adenocarcinoma

GenomeRNAi Phenotypes related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 9.95 MET
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.95 MET
3 Increased shRNA abundance (Z-score > 2) GR00366-A-119 9.95 MET
4 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.95 ERCC1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.95 PTEN
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.95 PTEN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.95 ERBB2 ERCC1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.95 ERBB2 PTEN
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.95 ERCC1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.95 MTHFR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-18 9.95 ERCC1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.95 MTHFR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.95 ERCC1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.95 MET
15 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.95 MET
16 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.95 MET
17 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.95 ERCC1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.95 ERBB2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 MTHFR PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.95 ERBB2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.95 MET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.95 MET
23 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 PTEN
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.95 MTHFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.95 MTHFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.95 ERBB2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.95 ERBB2 ERCC1 MET PTEN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.95 PTEN
29 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.95 MTHFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.95 MET
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 ERBB2 ERCC1 MET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.95 ERBB2 PTEN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.95 PTEN

MGI Mouse Phenotypes related to Gastroesophageal Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 EGFR ERBB2 ERCC1 ERCC2 MET MST1R
2 integument MP:0010771 9.97 EGFR ERBB2 ERCC1 ERCC2 GSTP1 MTHFR
3 neoplasm MP:0002006 9.85 EGFR ERBB2 ERCC1 ERCC2 GSTP1 MET
4 limbs/digits/tail MP:0005371 9.8 EGFR ERBB2 MET MTHFR PTEN SRC
5 pigmentation MP:0001186 9.35 EGFR ERCC2 PTEN SRC XPA
6 reproductive system MP:0005389 9.28 EGFR ERBB2 ERCC1 ERCC2 MST1R MTHFR

Drugs & Therapeutics for Gastroesophageal Adenocarcinoma

Drugs for Gastroesophageal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
2
Fluorouracil Approved Phase 4 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 6857599 43805
4
leucovorin Approved Phase 4 58-05-9 6006
5
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
6 Immunologic Factors Phase 4
7 Antimetabolites Phase 4
8 Micronutrients Phase 4
9 Antidotes Phase 4
10 Trace Elements Phase 4
11 Nutrients Phase 4
12 Vitamin B9 Phase 4
13 Immunosuppressive Agents Phase 4
14 Hormones Phase 4
15 Folate Phase 4
16 Vitamin B Complex Phase 4
17 Protective Agents Phase 4
18 Vitamins Phase 4
19 Calcium, Dietary Phase 4
20 Folfirinox Phase 4
21
Calcium Nutraceutical Phase 4 7440-70-2 271
22
Epirubicin Approved Phase 3 56420-45-2 41867
23
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
24
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
25
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
26
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
27
Lenvatinib Approved, Investigational Phase 3 417716-92-8
28 Antibiotics, Antitubercular Phase 3
29 Anti-Bacterial Agents Phase 3
30 Antimitotic Agents Phase 2, Phase 3
31 Albumin-Bound Paclitaxel Phase 2, Phase 3
32 Tubulin Modulators Phase 2, Phase 3
33 Protein Kinase Inhibitors Phase 3
34
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
35
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
36
Bevacizumab Approved, Investigational Phase 2 216974-75-3
37
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
38
Rucaparib Approved, Investigational Phase 1, Phase 2 283173-50-2 9931954
39
ramucirumab Approved, Investigational Phase 2 947687-13-0
40
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
41
nivolumab Approved Phase 2 946414-94-4
42
Pembrolizumab Approved Phase 2 1374853-91-4
43
Floxuridine Approved Phase 2 50-91-9 5790
44
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
45
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
47
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
48
Rilotumumab Investigational Phase 2 872514-65-3
49 Hematinics Phase 2
50 taxane Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
2 Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial Unknown status NCT02780921 Phase 3
3 Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
4 Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) Recruiting NCT04662710 Phase 3 Oxaliplatin;Capecitabine;Leucovorin (or Levoleucovorin);5-FU
5 PreOperative Treatment With chEmotheRapy or chemoRAdiatioN in esophaGeal or gastroEsophageal adenocaRcinoma Recruiting NCT01404156 Phase 2, Phase 3 (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
6 MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial Completed NCT01443065 Phase 2 Oxaliplatin;Folinic Acid;5-fluoro-uracil;panitumumab;AMG102
7 A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction Completed NCT00073502 Phase 2 OSI-7904L
8 A Single Arm Phase II Feasibility Study of Neoadjuvant Docetaxel, Oxaliplatin and S-1 Chemotherapy in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma. Completed NCT00816543 Phase 2 DOCETAXEL;S-1;OXALIPLATIN
9 Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma Completed NCT01231399 Phase 1, Phase 2 fluorouracil;leucovorin calcium;oxaliplatin;everolimus
10 A Phase II Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma Completed NCT00390416 Phase 2 Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
11 An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma Completed NCT01757171 Phase 2 Cabazitaxel
12 A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations Recruiting NCT04604132 Phase 1, Phase 2 Derazantinib;Derazantinib-paclitaxel-ramucirumab;Derazantinib-atezolizumab;Paclitaxel-ramucirumab
13 Avelumab + Paclitaxel/ Ramucirumab as Second Line Treatment in Gastro-esophageal Adenocarcinoma: a Phase II Trial of the AIO (The RAP-Trial) Recruiting NCT03966118 Phase 2 Avelumab;Ramucirumab;Paclitaxel
14 A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME) Recruiting NCT03995017 Phase 1, Phase 2 Rucaparib;Ramucirumab;Nivolumab
15 Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Recruiting NCT04021108 Phase 2 Nivolumab 240 MG
16 Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma (GEA) Recruiting NCT03929666 Phase 2 ZW25 (Zanidatamab);Capecitabine;Cisplatin;Fluorouracil;Leucovorin;Oxaliplatin
17 Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC) Recruiting NCT04164979 Phase 2 Cabozantinib;Pembrolizumab
18 A Phase II Trial of Neoadjuvant Pembrolizumab for Resectable Early Stage Gastroesophageal Adenocarcinoma Recruiting NCT04089904 Phase 2 Pembrolizumab Injection
19 A Prospective, Multicenter, Single-armed, Phase II Study Evaluating Efficacy and Safety of Neoadjuvant Sintilimab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma. Recruiting NCT04065282 Phase 2 Sintilimab;Oxaliplatin;Capecitabine
20 Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer Active, not recruiting NCT02317991 Phase 2 nab-paclitaxel
21 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Active, not recruiting NCT02213289 Phase 2 Trastuzumab;ABT-806;TBD2;Ramucirumab;Nivolumab
22 A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas Active, not recruiting NCT03783936 Phase 2 Oxaliplatin;Leucovorin;5 fluorouracil;Trastuzumab;Avelumab
23 Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 Active, not recruiting NCT03997448 Phase 2 Pembrolizumab;Abemaciclib
24 FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma. The LOGIC Study Terminated NCT03528876 Phase 2 FOLFOX and FOLFIRI
25 A Randomized Phase-II Study of Patients With Locally Advanced Gastric of Gastro-Esophageal Adenocarcinoma Treated With Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine, Followed by Prolonged Administration of Capecitabine Terminated NCT00848783 Phase 2 Irinotecan;Cisplatin;Floxuridine;Capecitabine
26 Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma Terminated NCT01980810 Phase 2 albumin-bounded paclitaxel;S-1
27 A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas. Terminated NCT00177255 Phase 2 Docetaxel;Capecitabine
28 A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma Terminated NCT01182610 Phase 2 Panitumumab;Paclitaxel;Carboplatin;5FU
29 A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma Terminated NCT00667420 Phase 1, Phase 2 panitumumab, epirubicin, oxaliplatin, xeloda
30 A Phase II Study Of Cabazitaxel For Metastatic Gastroesophageal Adenocarcinomas That Have Relapsed After At Least One Line Of Chemotherapy Terminated NCT01365130 Phase 2 jevtana
31 A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma Withdrawn NCT02344810 Phase 1, Phase 2 c-Met inhibitor AMG 337;oxaliplatin;leucovorin calcium;fluorouracil
32 A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma Completed NCT02138929 Phase 1 Everolimus;LDE 225
33 Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery Recruiting NCT04391049 Phase 1 Carboplatin;Paclitaxel
34 A Phase Ib Multicenter Study of TAS-102 in Combination With Irinotecan in Patients With Advanced Recurrent or Unresectable Gastric and Gastroesophageal Adenocarcinoma After at Least One Line of Treatment With a Fluoropyrimidine and Platinum Containing Regimen Active, not recruiting NCT04074343 Phase 1 TAS-102;Irinotecan
35 An Umbrella Study to Evaluate MLN1117 in Combination With Taxanes (Docetaxel or Paclitaxel) and Other Investigational Anticancer Agents for the Treatment of Patients With Previously Treated Advanced and Metastatic Gastric and Gastroesophageal Adenocarcinoma Terminated NCT02551055 Phase 1 MLN1117;TAK-659;Alisertib;Paclitaxel;Docetaxel
36 Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study Recruiting NCT04219137
37 Pilot Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma Recruiting NCT03784326 Early Phase 1 Atezolizumab;Fluorouracil;Oxaliplatin
38 A Pilot Study of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma Recruiting NCT03395847 Early Phase 1
39 Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas Active, not recruiting NCT04669951

Search NIH Clinical Center for Gastroesophageal Adenocarcinoma

Genetic Tests for Gastroesophageal Adenocarcinoma

Anatomical Context for Gastroesophageal Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Adenocarcinoma:

40
Breast, Lung, Thyroid, Skin, Ovary, Skeletal Muscle, Bone Marrow

Publications for Gastroesophageal Adenocarcinoma

Articles related to Gastroesophageal Adenocarcinoma:

(show top 50) (show all 242)
# Title Authors PMID Year
1
Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). 61
33760115 2021
2
Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer. 61
33770461 2021
3
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. 61
33798656 2021
4
Adherence to and determinants of guideline- recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. 61
33730386 2021
5
Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses. 61
32997798 2021
6
High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. 61
31425286 2021
7
Role of Radiation Therapy in Gastric Cancer. 61
33689079 2021
8
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? 61
33742317 2021
9
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma. 61
33755863 2021
10
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. 61
33739449 2021
11
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. 61
33234578 2021
12
Dissecting Response to Cancer Immunotherapy by Applying Bayesian Network Analysis to Flow Cytometry Data. 61
33652558 2021
13
Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. 61
33609722 2021
14
Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: Implications for claudin 18.2 monoclonal antibody therapy. 61
33590909 2021
15
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. 61
32040809 2021
16
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. 61
33436042 2021
17
Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies. 61
33353828 2020
18
Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. 61
32737700 2020
19
Progress and challenges in gastroesophageal cancer. 61
32451067 2020
20
ISH-based HER2 diagnostics. 61
33346874 2020
21
Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. 61
32820017 2020
22
Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. 61
33170336 2020
23
[ISH-based HER2 diagnostics]. 61
33001242 2020
24
Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. 61
32965540 2020
25
Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. 61
32891647 2020
26
Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. 61
32719550 2020
27
Secondary adenocarcinoma of the urinary bladder attributed to metastatic gastroesophageal cancer. 61
33049197 2020
28
Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. 61
32971757 2020
29
HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology. 61
32825958 2020
30
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. 61
32469386 2020
31
Targeted Therapies in Advanced Gastric Cancer. 61
32725377 2020
32
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. 61
32167861 2020
33
Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. 61
31927675 2020
34
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. 61
32388292 2020
35
Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. 61
32141500 2020
36
The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. 61
32576019 2020
37
Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. 61
32130793 2020
38
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma. 61
32220925 2020
39
Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. 61
32338752 2020
40
Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. 61
31918022 2020
41
Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. 61
31720832 2020
42
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. 61
32058557 2020
43
What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center. 61
31736219 2020
44
Next generation sequencing in gastric or gastroesophageal adenocarcinoma. 61
33073051 2020
45
Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach. 61
32023907 2020
46
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. 61
31570517 2020
47
ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution. 61
33426545 2020
48
Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. 61
32998149 2020
49
Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma. 61
33194593 2020
50
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. 61
31655359 2019

Variations for Gastroesophageal Adenocarcinoma

Expression for Gastroesophageal Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Adenocarcinoma.

Pathways for Gastroesophageal Adenocarcinoma

Pathways related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.89 SRC MST1R MET ERBB2 EGFR
2
Show member pathways
12.84 SRC PTEN MET ERBB2 EGFR
3
Show member pathways
12.8 UMPS UGT1A1 GSTT1 GSTP1 GSTM1
4
Show member pathways
12.74 SRC PTEN GSTP1 ERBB2 EGFR
5
Show member pathways
12.67 SRC PTEN MET ERBB2 EGFR
6 12.64 PTEN MET GSTT1 GSTP1 GSTM1 ERBB2
7
Show member pathways
12.62 SRC PTEN MET ERBB2 EGFR
8
Show member pathways
12.47 PTEN MET GSTT1 GSTP1 GSTM1 ERBB2
9
Show member pathways
12.45 PTEN MET ERBB2 EGFR
10
Show member pathways
12.41 SRC PTEN MET ERBB2 EGFR
11 12.34 MST1R MET ERBB2 EGFR
12
Show member pathways
12.34 SRC MST1R MET ERBB2 EGFR
13 12.27 XRCC1 XPA TYMS GSTP1 ERCC2 ERCC1
14
Show member pathways
12.26 SRC PTEN ERBB2 EGFR
15 12.25 SRC MET ERBB2 EGFR
16
Show member pathways
12.15 SRC PTEN MET ERBB2 EGFR
17 12.12 SRC PTEN ERBB2 EGFR
18
Show member pathways
12.07 SRC PTEN ERBB2 EGFR
19 12.03 SRC GSTT1 GSTP1 GSTM1
20 11.97 SRC MST1R MET ERBB2 EGFR
21
Show member pathways
11.81 SRC MET EGFR
22 11.8 SRC PTEN EGFR
23
Show member pathways
11.71 UGT1A1 GSTT1 GSTP1 GSTM1
24 11.69 SRC ERBB2 EGFR
25
Show member pathways
11.67 UMPS TYMS MTHFR ERCC2
26 11.65 SRC ERBB2 EGFR
27 11.63 SRC MET ERBB2 EGFR
28 11.6 PTEN MET ERBB2 EGFR
29 11.55 SRC ERBB2 EGFR
30 11.47 UGT1A1 SRC EGFR
31 11.43 SRC ERBB2 EGFR
32 11.31 SRC MET EGFR
33 11.3 XPA GSTT1 GSTP1 GSTM1 ERCC1 ERBB2
34 11.27 SRC MET EGFR
35 11.19 MET ERBB2 EGFR
36 11.08 GSTT1 GSTP1 GSTM1
37 10.95 MST1R MET ERBB2 EGFR
38 10.79 UGT1A1 GSTT1 GSTP1
39 10.56 XPA GSTT1 GSTP1 GSTM1 ERCC2 ERCC1

GO Terms for Gastroesophageal Adenocarcinoma

Cellular components related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.17 XPA UMPS UGT1A1 TYMS SRC PTEN
2 receptor complex GO:0043235 9.56 MST1R MET ERBB2 EGFR
3 ERCC4-ERCC1 complex GO:0070522 9.16 XRCC1 ERCC1
4 nucleotide-excision repair factor 1 complex GO:0000110 8.96 XPA ERCC1
5 basal plasma membrane GO:0009925 8.92 MST1R MET ERBB2 EGFR

Biological processes related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 10.06 PTEN MTR MST1R MET ERBB2
2 cell migration GO:0016477 9.96 SRC PTEN MST1R MET
3 response to organic cyclic compound GO:0014070 9.88 UGT1A1 TYMS PTEN EGFR
4 cellular response to insulin stimulus GO:0032869 9.85 SRC PTEN GSTP1
5 response to organic substance GO:0010033 9.85 XRCC1 UGT1A1 PTEN
6 response to ethanol GO:0045471 9.85 UGT1A1 TYMS PTEN GSTP1
7 liver development GO:0001889 9.84 UGT1A1 MET EGFR
8 response to nutrient GO:0007584 9.82 UGT1A1 PTEN ERCC1
9 glutathione metabolic process GO:0006749 9.79 GSTT1 GSTP1 GSTM1
10 cellular response to epidermal growth factor stimulus GO:0071364 9.78 GSTP1 ERBB2 EGFR
11 nucleotide-excision repair GO:0006289 9.77 XPA ERCC2 ERCC1
12 nucleotide-excision repair, DNA incision GO:0033683 9.77 XPA ERCC2 ERCC1
13 positive regulation of protein kinase B signaling GO:0051897 9.77 SRC MST1R MET ERBB2 EGFR
14 nucleotide-excision repair, DNA incision, 5'-to lesion GO:0006296 9.76 XPA ERCC2 ERCC1
15 positive regulation of kinase activity GO:0033674 9.73 MST1R MET ERBB2 EGFR
16 regulation of ERK1 and ERK2 cascade GO:0070372 9.71 GSTP1 ERBB2 EGFR
17 transcription-coupled nucleotide-excision repair GO:0006283 9.71 XRCC1 XPA ERCC2 ERCC1
18 ERBB2 signaling pathway GO:0038128 9.7 SRC ERBB2 EGFR
19 global genome nucleotide-excision repair GO:0070911 9.69 XPA ERCC2 ERCC1
20 hepatocyte growth factor receptor signaling pathway GO:0048012 9.67 MST1R MET
21 glutathione derivative biosynthetic process GO:1901687 9.67 GSTT1 GSTP1 GSTM1
22 UV-damage excision repair GO:0070914 9.65 XPA ERCC1
23 methionine biosynthetic process GO:0009086 9.65 MTR MTHFR
24 nucleotide-excision repair, DNA incision, 3'-to lesion GO:0006295 9.65 XPA ERCC2 ERCC1
25 tetrahydrofolate metabolic process GO:0046653 9.64 TYMS MTHFR
26 tetrahydrofolate interconversion GO:0035999 9.64 TYMS MTHFR
27 response to folic acid GO:0051593 9.63 TYMS MTHFR
28 hepoxilin biosynthetic process GO:0051122 9.63 GSTP1 GSTM1
29 nucleotide-excision repair, preincision complex stabilization GO:0006293 9.63 XPA ERCC2 ERCC1
30 response to drug GO:0042493 9.63 XRCC1 UGT1A1 TYMS SRC PTEN MTHFR
31 entry of bacterium into host cell GO:0035635 9.62 SRC MET
32 negative regulation of ERBB signaling pathway GO:1901185 9.62 ERBB2 EGFR
33 negative regulation of protection from non-homologous end joining at telomere GO:1905765 9.57 XRCC1 ERCC1
34 telomeric DNA-containing double minutes formation GO:0061819 9.56 XRCC1 ERCC1
35 positive regulation of MAP kinase activity GO:0043406 9.56 SRC MST1R ERBB2 EGFR
36 UV protection GO:0009650 9.5 XPA ERCC2 ERCC1
37 peptidyl-tyrosine phosphorylation GO:0018108 9.35 SRC MST1R MET ERBB2 EGFR
38 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.02 SRC MST1R MET ERBB2 EGFR

Molecular functions related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.85 SRC MST1R MET ERBB2 EGFR
2 protein C-terminus binding GO:0008022 9.73 SRC ERCC2 ERCC1 ERBB2
3 transferase activity GO:0016740 9.7 UMPS UGT1A1 TYMS SRC MTR MST1R
4 protein phosphatase binding GO:0019903 9.67 MET ERBB2 EGFR
5 damaged DNA binding GO:0003684 9.62 XRCC1 XPA ERCC2 ERCC1
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 MST1R MET ERBB2 EGFR
7 protein tyrosine kinase activity GO:0004713 9.55 SRC MST1R MET ERBB2 EGFR
8 glutathione transferase activity GO:0004364 9.54 GSTT1 GSTP1 GSTM1
9 glutathione binding GO:0043295 9.48 GSTP1 GSTM1
10 3' overhang single-stranded DNA endodeoxyribonuclease activity GO:1990599 9.4 XRCC1 ERCC1
11 enzyme binding GO:0019899 9.17 XRCC1 UGT1A1 SRC PTEN MST1R GSTM1

Sources for Gastroesophageal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....